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Accepted 13 November 2017; Published online 20 November 2017AbstractObjectives: Randomization can be used as an instrumental variable (IV) to account for unmeasured confounding when seeking to
assess the impact of noncompliance with treatment allocation in a randomized trial. We present and compare different methods to calculate
the treatment effect on a binary outcome as a rate ratio in a randomized surgical trial.
Study Design and Setting: The effectiveness of peeling versus not peeling the internal limiting membrane of the retina as part of the
surgery for a full thickness macular hole. We compared the IV-based estimates (nonparametric causal bound and two-stage residual inclu-
sion approach [2SRI]) with standard treatment effect measures (intention to treat, per protocol and treatment received [TR]). Compliance
was defined in two ways (initial and up to the time point of interest). Poisson regression was used for the model-based approaches with
robust standard errors to calculate the risk ratio (RR) with 95% confidence intervals.
Results: Results were similar for 1-month macular hole status across methods. For 3- and 6-month macular hole status, nonparametric
causal bounds provided a narrower range of uncertainty than other methods, though still had substantial imprecision. For 3-month macular
hole status, the TR estimate was substantially different from the other point estimates.
Conclusion: Nonparametric causal bound approaches are a useful addition to an IV estimation approach, which tend to have large
levels of uncertainty. Methods which allow RRs to be calculated when addressing noncompliance in randomized trials exist and may be
superior to standard estimates. Further research is needed to explore the properties of different IV methods in a broad range of randomized
controlled trial scenarios.  2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Randomized controlled trials (RCTs) are widely seen as
the optimal way to evaluate the effect of treatments. How-
ever, the design, conduct, and analysis of an RCT can un-
dermine the purpose of randomization and introduce bias
in the estimation of treatment effects. Departures fromConflicts of interest: None.
* Corresponding author. Centre for Statistics in Medicine, University
of Oxford, Botnar Reserach Centre, Oxford OX37LD, UK. Tel.: 01865
223 450.
E-mail address: jonathan.cook@ndorms.ox.ac.uk (J.A. Cook).
https://doi.org/10.1016/j.jclinepi.2017.11.011
0895-4356/ 2017 The Authors. Published by Elsevier Inc. This is an open acces
4.0/).random allocation (often referred to as noncompliance or
nonadherence) create uncertainty in the interpretation of
findings with regard to the causal effect of treatment.
Although an intention-to-treat (ITT)ebased analysis re-
mains the default analysis [1e3], in the presence of sub-
stantial noncompliance, it is natural to ask the question
‘‘what is the effect of actually receiving the treatment?’’
Two common approaches used to address noncompli-
ance are per-protocol (PP) and treatment-received (TR) an-
alyses. Under a PP analysis, only data from those
participants deemed to have complied with the (treatment)
protocol are included. In a TR analysis, the analysis groups
are formed on the basis of the actual TR, irrespective of the
randomized treatment. The shortcomings of theses article under the CC BY license (http://creativecommons.org/licenses/by/
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Key findings
 Across the different time points and noncompli-
ance definitions for the case study, the point esti-
mates of the various methods were generally
similar.
 The nonparametric casual bound approach pro-
duced a narrow range of uncertainty than the risk
ratio confidence interval of the two-stage residual
inclusion instrumental variable (IV) method and
standard intention to treat, per protocol and treat-
ment received estimates.
What this adds to what was known?
 This article compared conventional analyses for
dealing with noncompliance in a randomized
controlled trial with two IVapproaches for a binary
outcome.
 The assumptions, advantages, and disadvantages of
the approaches are considered using a surgical trial
with substantial receipt of the nonallocated treat-
ment over the follow-up period (‘‘noncompliance’’).
What is the implication and what should change
now?
 The nonparametric causal bounds approach for bi-
nary outcome may be more informative than the
standard method to address noncompliance in a
trial in some situations.
 The generalizability of the finding should be
explored across a range of settings and levels of
treatment effect and noncompliance.
J.A. Cook et al. / Journal of Clinconventional approaches to dealing with noncompliance are
well recognized [1,3]. Those who do not comply with treat-
ment allocation (e.g. did not get surgery as allocated) tend
to be different from the typical participant (they are often
sicker and poorer in health, though in some situations the
reverse can be true). A PP analysis excludes the subset of
participants who do not comply from the analysis risk
potentially introducing selection bias, as those who comply
may reflect different patient characteristics between the
groups. The TR analysis is carried out on the basis of trans-
ferring individuals who ‘‘crossed over’’ to the other group,
and so also introduces bias into the comparison.
More recently, causal methods which address noncom-
pliance while maintaining the integrity of randomization
and avoiding exclusions of participants have been proposed
[3e5], which vary in complexity and the underlying as-
sumptions. Focus has mainly been on continuous outcomes[2,4,6e8] partly through the more ready application of
methods, although approaches for binary outcomes do exist
[1,4,5,9,10]. Their use has been limited, and when used, the
focus has been on calculating the risk difference and in the
setting of an observational study [11,12]. In particular,
causal bound instrumental variable (IV) methods have
received little attention but can be readily calculated when
the instrument, exposure variable, and the outcome are bi-
nary [9]. Surgery is considered an example of a scenario
where compliance issues are ‘‘simple’’ (i.e., surgery is or
is not received) as opposed to drug treatment or complex
interventions which are delivered over time [5]. However,
the recent work has highlighted the potential complexity
of surgical interventions [13e15]. The use of compliance-
based trial analyses in the area of surgery has been very
limited to date, and methodological considerations have
focused on surgery versus medicine and for a continuous
outcome [16]. The aim of the work presented herein is to
explore the compliance in a surgical randomized trial,
where the treatment effect for a binary primary outcome
is expressed as a risk ratio (RR). Through the case study,
we seek to illustrate the use of randomization respecting
compliance analyses versus conventional methods and to
consider issues relating to compliance in this setting.1.1. Case studyeFILMS trial
The Full Thickness Macular Hole and Internal Limiting
Membrane Peeling Study (FILMS) trial compared macular
hole surgery with or without peeling (removal) of the inter-
nal limiting membrane (ILM) of the retina for idiopathic
full thickness macular holes (FTMH) [17,18]. Macular hole
surgery, which seeks to close the hole and improve patient
visual outcome, involves a number of steps with peeling an
optional additional step. Patients with stage 2 or 3 FTMH
were randomized to receive macular hole surgery with or
without ILM peeling or not at nine centers. Of the 141 par-
ticipants randomized, 138 were included in the statistical
analysis (three were discovered not to meet the eligibility
criteria after being randomized). The status of the macular
hole (open or closed), the main surgical outcome, was as-
sessed at 1, 3, and 6 months after surgery. Other outcomes
collected included visual function (EDTRS visual acuity in
the study eye [the primary outcome] and the fellow eye)
and quality of life (Visual Function Questionnaire-25 and
EuroQol 5 Dimensions 3 Levels). Principal (ITT based)
study analyses found evidence of decreased occurrence of
an open hole at 1 month but no statistical evidence of dif-
ference at 3 and 6 months [17]. However, interpretation of
these findings was complicated by the occurrence of further
surgery with 29 (43%) of the nonpeeling group received
peeling within the 6-month follow-up period (Table 1).
Some occurrences of peeling within this group were as
per the initial treatment and some as a further surgical inter-
vention, which was allowed in FILMS according to stan-
dard clinical care. Although a number of factors could
Table 1. Number of participants who received peeling by randomized
group (N [%])
Time from
baseline
Peeling group
(n [ 71)
No peeling group
(n [ 67)
1 month 64 (90) 4 (6)
3 months 64 (90) 27 (40)
6 months 64 (90) 29 (43)
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latter time points (3 and 6 months), it was thought to be
most likely caused by the substantial number receiving
peeling in the control group. A later individual patient data
meta-analysis which included the FILMS trial provided
further support for this view [19]. Although participants
receiving peeling in the no peel group if their initial treat-
ment was deemed to fail can be viewed as both clinically
necessary and allowable within the trial protocol, from an
evaluation perspective, it can also be viewed as ‘‘noncom-
pliance’’ and an obstacle to an accurate assessment of the
effect of actually receiving the treatment.2. Methods
2.1. Scenario
The following considers the situation where we have a
2-arm RCTwith treatment allocation (Z ), a binary outcome
(Y ), and a binary measure of receipt of the treatment (D).
We define compliance as a participant receiving their
randomly allocated treatment (Z 5 D). In addition, we
acknowledge the possibility of a vector of variables, U,
which are unmeasured confounders of the outcome and
compliance. Fig. 1 represents this graphically. An estimate
of the treatment effect on outcome which accounts for the
presence of noncompliance with treatment allocation is
desired. The presence of U results in bias under conven-
tional methods, such as excluding those who do not comply
(PP) or direct adjustment in the statistical analysis. One
way to deal with this is the use of an IV approach, in this
setting of random allocation (Z ), which enables the influ-
ence of U to be controlled for. A valid IV has to meet three
standard IV assumptions: (1) the IV, Z, is assumed to be in-
dependent of U; (2) the TR (D) is assumed not to be inde-
pendent of the IV (i.e., Z ), which here implies that the
random allocation influences the TR (D); and (3) the
outcome (Y ) is assumed to be independent of randomFig. 1. Graphical representation of a trial with noncompliance, with
randomization as an instrumental variable for the treatment received.allocation, given knowledge of the unobserved confounder
and the TR, which implies that the random allocation only
influences the outcome through the TR. This last assump-
tion is referred to as the ‘‘exclusion restriction’’ [3]. A
further assumption, most commonly a monotonicity
assumption (e.g., the absence of ‘‘defiers’’, individuals
who will always receive the opposite of their random allo-
cation), is assumed to enable the local average treatment ef-
fect, also called the complier average causal effect (CACE),
to be estimated [20,21]. Other distributional assumptions
that can be made about the relationships of Y to U and D
(e.g., additivity on the chosen outcome scale of interest
and assuming a particular model form) are also commonly
made to allow estimation of the point estimate and associ-
ated uncertainty [1]. For simplicity and to allow direct
comparability between methods, the presence of observed
confounders (such as might be used in the randomization
algorithm, and in the case study, a prognostic factor such
as stage of macular hole) has been ignored throughout,
although the general approach can be extended, given
appropriate assumptions to allow for controlling for these
(e.g., through a regression model), as per the ITT analysis.
Compliance (and noncompliance) was defined as receipt
(or not) of the allocated treatment, irrespective of the reason
for any deviation from allocation. In our case study, three
different definitions of compliancewere used: (1) compliance
to the presence or absence of peeling during the initial surgery
(C1); (2) compliance to the undertake peeling or not up to
3 months after surgery (C2); and (3) compliance to the under-
taking of peeling or not up to 6 months after surgery (C3).2.2. Comparison of methods
The three classic conventional analyses were conducted;
ITT, estimating the causal effect of random allocation where
participants are analyzed according to the randomized
groups irrespective of receipt of treatment (i.e., the effect
of Z on Y ); PP, where analysis was according to randomized
group using the available data for those viewed as complaint
(i.e., the effect of Z on Y in those for whom Z 5 D); and TR
where the participants were grouped according to the actual
TR up to the corresponding time point, irrespective of the
random allocation (i.e., the effect of D on Y ). It should be
noted that the term ‘‘ITT’’ is not used here in the strict sense
as there was a small amount of missing data for the primary
outcome, and three ineligible participants were excluded
postrandomization. For the purposes of this case study com-
parison, to match the trial’s principal analysis, and for
simplicity of presentation, the impact of this not been consid-
ered here. An unadjusted Poisson regression model with
robust standard errors was used to calculate three conven-
tional treatment effects and the associated uncertainty at
the 5% 2-sided significance level (via 95% confidence inter-
val [CI] and P-value) with the effect expressed as an RR.
In addition, two IV methods were used in which random
allocationwas used as an IV to allow an unbiased causal effect
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factors (e.g., receipt of the treatment being influenced by
another unmeasured factor such as surgeon treatment prefer-
ence). The two IV analyses used were as follows:
1. A causal bounds (cbounds) approach in which bounds
for the average treatment effect were calculated using
the bpbounds command in Stata [9]. Under this
approach, no point estimate is calculated but instead
bounds for the causal effect for which a distribution
exists given the underlying standard IV assumptions.
Together, the IV assumptions impose constraints on
the causal risk ratio for a binary outcome, and bounds
can be calculated. In this context, it allows the bound-
ing of the effect on receiving the treatment in the trial
(‘‘global’’) population. Details on how this can be
achieved are given in the Online appendix along with
the additional invoking of a monotonicity assumption.
2. A two-stage residual inclusion estimator approach
(2SRI) [1,22]. This IV approach differs from the
causal bounds approach in that further assumptions
are made to estimate the point estimate of the causal
effect. This leads to a local estimate of the treatment
effect among those who would comply with the allo-
cated treatments. Under this method, the residuals
from a regression of TR on randomization (first stage)
were obtained to enable an unbiased analysis of the
effect of receiving treatment on outcome in the com-
pliers (second stage). This second stage was carried
out using an unadjusted Poisson regression model
for the treatment effect by regression of the outcome
on the TR (with 95% CI calculated) adjusted for the
first-stage residuals as covariates. The model can be
formulated as:Table 2
groups
Key ba
mean (
Age
Stage
EDTRS
EDTRS
EuroQ
VisualY|PoissonðrÞ;
where logeðrÞ5b0 þ b1Dþ b2E and E is the residual from
the first-stage least squares linear regression of TR (D) to
the instrument (Z ) such thatE5D ðba0 þ ba1ZÞ
where ba0 and ba1 are the estimated regression coefficients
from the first-stage regression.. Full Thickness Macular Hole and Internal Limiting Membrane Peelin
at 6 months
seline measures,
SD)
Randomized group
Peel
(n [ 71)
No Peel
(n [ 67)
70 (6) 71 (6)
of hole (stage 3), n (%) 42 (59) 41 (61)
visual acuity study eye 48 (14) 50 (11)
visual acuity fellow eye 76 (14) 76 (17)
ol 5 Dimensions 3 Levels 0.80 (0.21) 0.88 (0.13)
Function Questionnaire-25 80 (16) 80 (18)The 2SRI estimate for a binary outcome is the same as
the adjusted IV of Palmers et al. [10] and equivalent to Na-
gelkerke and colleagues’ adjusted treatment received
approach to estimate the causal effect in the presence of
noncompliance [1]. After the second stage of estimation,
the standard errors of the estimates were corrected using
the method of Terza [23].
3. Results
3.1. Randomization as an IV in the FILMS study
Compliance status is presented in Table 1 using the
aforementioned three definitions. Baseline values for key
variables are presented by the randomized groups and/or
by compliance status in Table 2. Macular hole closure find-
ings (the outcome) are provided at 1, 3, and 6 months in
Table 3. The proportion complying is similar at 1 month
and markedly different at 3 and 6 months suggested that
a PP analysis is at the risk of substantial bias when
following the protocol is defined as through the follow-up
period (C2 and C3). Regarding the IV assumptions,
randomization, if correctly implemented, precludes the pos-
sibility of an association between random allocation and
any pre-existing unmeasured confounders. For each of the
compliance definitions, it is worth noting receipt of alloca-
tion to peeling was associated with greater receipt of
peeling as would be anticipated in an RCT (i.e., more indi-
viduals allocated to peeling received peeling than those
allocated to no peeling) supporting acceptance of core IV
assumption (2). The distribution of the variables were
checked to see if they were consistent with the core IV as-
sumptions. Baseline data from the FILMS trial are pre-
sented in Table 2 by randomized group and by
compliance status. Key trial outcomes did not appear to
differ greatly by compliance, although this does not clarify
the status of unmeasured cofounders which by definition
cannot be directly checked. Given the two treatments of in-
terest were the same bar, the additional step of peeling, the
third IV assumption (3) would also seem very plausible.
3.2. Comparison of analyses
Table 4 shows the results using two compliance defini-
tions for different methods for the various treatment effectg Study trialdbaseline variables by randomized group and compliance
Compliance (6 months)
Compliers (6 months) by
randomized groups
Complier
(n [ 102)
Noncomplier
(n [ 36)
Peel
(n [ 64)
No peel
(n [ 38)
71 (6) 71 (6) 70 (6) 71 (6)
58 (57) 25 (67) 38 (59) 20 (54)
48 (10) 48 (10) 48 (14) 52 (11)
78 (11) 78 (11) 76 (14) 75 (20)
0.84 (0.14) 0.84 (0.14) 0.80 (0.21) 0.90 (0.13)
79 (21) 79 (21) 79 (16) 82 (13)
Table 3. Macular hole status by time point and randomized group (N
[%] closed)
Time point
Randomized groups
Peeling group
(n [ 71)
No peeling group
(n [ 67)
1 month 56 (84) 31 (48)
3 months 61 (92) 52 (83)
6 months 61 (94) 56 (89)
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TR, 2SRI and PP (under compliance to the initial surgery)
analyses are all highly significant with large estimated RRs
(between 0.26 and 0.32). The ITT effect is the smallest esti-
mate. Interestingly, the causal bounds approach contains all
the estimated point estimates (0.24, 0.38) but is narrower
than all the estimated CIs. At 3 months, there is a similar
pattern; although most of the analyses now show no statisti-
cal evidence of a difference. However, the causal bounds
method shows evidence of a causal effect given initial
compliance. This is no longer true if compliance is based
on the absence of peeling through the 3-month follow-up
period. For 6 months under initial compliance, all the regres-
sion analyses provide a similar point estimate likely due to
no participants with 6-month data who both had an eventTable 4. Risk ratio results (95% CI/causal bounds)
Outcome Compliance Method
Point estimate
(lowereupper) P-value
1 month ITT 0.32 (0.18e0.58) 0.001
C1 PP 0.26 (0.14e0.51) !0.001
TR 0.25 (0.13e0.49) !0.001
2SRI 0.26 (0.13e0.53) !0.001
Causal
bounds
NA (0.24e0.38)
3 month ITT 0.43 (0.16e1.18) 0.103
C1 PP 0.35 (0.12e1.05) 0.061
TR 0.33 (0.11e0.97) 0.044
2SRI 0.37 (0.11e1.26) 0.112
Causal
bounds
NA (0.27e0.69)
C2 PP 0.35 (0.11e1.12) 0.078
TR 0.48 (0.19e1.20) 0.117
2SRI 0.20 (0.02e1.60) 0.129
Causal
bounds
NA (0.13e1.09)
6 month ITT 0.55 (0.17e1.81) 0.328
C1 PP 0.55 (0.17e1.80) 0.326
TR 0.55 (0.17e1.81) 0.328
2SRI 0.51 (0.13e1.99) 0.331
Causal
bounds
NA (0.39e0.97)
C3 PP 0.45 (0.13e1.68) 0.214
TR 0.51 (0.16e1.66) 0.238
2SRI 0.31 (0.03e3.84) 0.362
Causal
bounds
NA (0.12e1.36)
Abbreviations: CI, confidence interval; ITT, intention to treat; PP,
per protocol; TR, treatment received; 2SRI, two-stage residual inclu-
sion approach.and were noncompliant. The causal bounds method again
shows weak evidence of a causal effect. Under compliance
across the 6-month period, the 2SRI estimate is large than
under ITT, PP, and TR. The causal bound approach no
longer shows evidence of a causal effect. Across all 3- and
6-month analyses, the 2SRI estimates had a high degree of
uncertainty larger than any of the other approaches.4. Discussion
Departures from random allocation can create uncer-
tainty about the interpretation of trial results based on an
ITT analysis. Various approaches have been proposed to
allow an estimate of the effect of TR. We illustrated the
use of four approaches for a binary outcome based on esti-
mating an RR, including two IV-based methods. Binary
outcomes are often one of, if not the key outcome in ran-
domized trials [24], and compliance to treatment allocation
can rarely be taken for granted, which suggests that the po-
tential use of such methods (including the causal bounds
approach) as an ancillary analysis potentially have wide-
spread application. A similar bounding approach can in
principle be applied to a continuous outcome where a min-
imum and maximum value can be assumed for the
outcome, and further, more restrictive assumptions were
made [25]. The two-stage least squares IV approach can
also be used for a binary outcome to estimate the risk dif-
ference although it does not constraint the probability be-
tween zero and one [6]. The IV approaches used here can
and have been used in Mendelian randomization epidemi-
ology studies [9,10].
Interestingly, in our analyses, the causal bounds IV
approach produced a more precise and potentially useful
finding than the other IV-based analysis (2SRI), which
had very wide CIs. In addition, it also produced a more
precise estimate of the causal effect than the TR and PP
analyses as well as requiring less strong assumptions
regarding those who comply with allocation (i.e., absence
of selection bias). Two-stage residual inclusion approach
makes an additional assumption of linearity on the scale
of interest which may not be appropriate [1,10]. Similarly,
a two-stage fully linear approach could have been adopted
although it has been demonstrated this may not produce a
consistent estimator for ratios but could have been used to
calculate the risk difference [6,26]. Appropriate CIs are
not straightforward for any of the model-based IV analyses
further providing merit to the nonparametric causal bounds
approach. The lack of a point estimate could be viewed as
a substantial disadvantage of a causal bounds approach.
Accordingly, such approaches are sometimes referred to
as ‘‘partial identification’’ methods [25]. However, it is
worth noting the level of uncertainty around the point es-
timate from some of model-based IV analyses can reduce
the corresponding point estimate to little practical value.
The disadvantages of the PP and TR analyses are well
known [5], and the assumptions required to provide an
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do not differ in their characteristics from those who do not
comply). IV approaches avoid making this assumption
while preserving the benefits of randomization. However,
they require additional assumptions beyond that of random-
ized treatment allocation. The plausibility of these assump-
tions will vary according to the situation. In the FILMS trial
example, the assumption that randomization influence the
TR is not problematic. Similarly, the exclusion restriction
assumption also seems very plausible given both treatment
arms receive a surgical operation which differs only in
respect to a single component (peeling or not of the
ILM). A minor caveat is the small number of patients did
not have any surgery or additionally received another surgi-
cal intervention. The remaining IV assumption regarding
independence of the unmeasured confounders and the IV,
is partially met at least by random allocation, but, it is
possible that allocation had some impact on such factors
particularly given it was not possible due to the nature of
the trial to fully blind all individuals involved in the study.
The adjusted treatment received method required further
assumptions of monotonicity, and in our implementation,
additivity of effect of TR and the unmeasured confounders.
In this example, the benefits of the simple application of the
2SRI approach over a causal bounds approach is dubious
for the simple binary outcome setting. This problem of a
lack of precision applies more generally to approaches
which estimate the CACE [5,11]. The large effect of mac-
ular hole surgery (with or without) peeling is perhaps atyp-
ical though somewhat offsetting this was the relatively
small size of the trial. Recent work has focused on attempts
to increase the precision of such analyses given the large
level of uncertainty reflected in our analyses [5].
The change or not in outcome status over time as treat-
ment is received could provide a more precise estimate of
the treatment effect. A recent study compared a number
of methods (including IV and mixed model approaches)
for addressing noncompliance of a medical vs. surgical trial
compared in the setting of a continuous outcome with
repeated measures [16]. In principle, a similar approach
could be carried out for a binary outcome which makes
use of the repeated data although the robustness of any
formal interference (i.e., calculating a 95% CI) is unclear.
Another aspect not addressed here is the complication
generated by the presence of missing data. This could affect
both the precision of the estimates and also introduce bias.
Further research on this topic in needed to explore this.
Surgery might be considered a simple situation to
address compliance as it can be considered a one-off event,
which either occurs or does not [5]. However, even in this
context, we showed that different definitions of compliance
are possible. The reality of surgical trials, similar to many
other skill-dependent interventions in particular, does not
fully fit this situation as the intervention can sometimes
be repeated or delivered over a number of occasions, and
varying ways. The analyses reported here in a less complexsurgical trial (surgery versus surgery which differs only in a
minor way [27]) still make the simplification that peeling of
ILM was or was not carried out. However, a small number
of participants did not receive any surgery or received
another surgical intervention, or received another nontrial
surgical procedure during the follow-up period. In addition,
it is possible to repeat ILM peeling if the initial peeling was
not complete as occurred in two cases; similarly, this was
also not accounted for in the analysis. Finally, while we
have focused implicitly on more surgery orientated compli-
ance, the full intervention included a patient-dependent
postoperative component of posturing (lying face down af-
ter the operation for prolonged periods of time) [17,28].
Limitations in data collection and reporting hinder more
in-depth assessment of the impact of this aspect of compli-
ance. Nevertheless, the methods here provide at least some
statistical reassurance that the presumed interpretation of a
casual treatment effect of ILM peeling is correct even
though the ITT analyses did not always reflect this.
In conclusion, this study has illustrated the use of
different IV methods, which can be readily used to supple-
ment the ITT analysis to address compliance for a binary
outcome with the treatment effect expressed as an RR. A
surgical randomized trial was used to illustrate their use,
and the nonparametric causal bounds approach provided
more certainty about the treatment effect once accounting
for noncompliance. However, as highlighted, these methods
require further assumptions to be made beyond the ITT
analysis to assess a causal effect of treatment, and they tend
to produce imprecise estimates despite representing a
simplified scenario of the reality of compliance in a surgical
setting. Nevertheless, their use can aid the interpretation of
surgical trials in the presence of noncompliance, and we
encourage the more routine adoption of these techniques,
which allow the impact of compliance to be evaluated
without compromising the benefits of randomization.Acknowledgments
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